May 14, 2025, 08:49

Cancer Grand Challenge: Rewiring Cancer Cells

This challenge aims to pioneer novel approaches that rewire the internal signalling systems of cancer cells to reduce malignancy or induce self-destruction. By harnessing advances in synthetic biology and systems biology, teams will explore ways to shift cancer cell behavior away from oncogenesis, creating new therapeutic strategies that avoid common resistance mechanisms seen with targeted inhibitors.

Eligibility Criteria:

Open to global, interdisciplinary research teams
Must combine expertise in areas such as synthetic biology, AI, medicinal chemistry, structure-based drug design, cancer biology, immunology, and cellular signalling
Proposals must not focus on targeted protein degradation

Funding Details:

Up to £20 million (USD 25 million) per team
Duration: Not specified

Deadline:

Expressions of Interest due: 18 June 2025

More Information:

Submit your Expression of Interest

cancer Cancer Cell Signalling Cancer Grand Challenge cancer therapy cancer treatment innovation cell phenotype modulation immunogenic cell death OncoDaily oncogenic signalling Oncology rewiring cancer Synthetic Biology tumour heterogeneity

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening